Shots:

• The launch of VENTANA PD-L1 (SP142) follows the US FDA’s approval in Mar’2019- as the first CDx assay involved in identifying triple-negative breast cancer (TNBC) patients associated with 3 proteins estrogen receptor- progesterone receptor and HER2/neu eligible for treatment with Tecentriq combination
• The assay is developed for the enhancement of visual contrast of tumor-infiltrating immune cell staining and was also used in enrolling the patients in IMpassion 130 trial assessing Tecentriq and evaluated patients with PD-L1 biomarker using immune cell screening and scoring in tumor cells
• The VENTANA PD-L1 (SP142) Assay is an automated BenchMark IHC/ISH series instrument utilizes OptiView DAB IHC Detection Kit with OptiView Amplification Kit and is involved in performing staining of tumor cells and immune cells- also FDA approved and CE marked assay  

Click here to read full press release/ article

 Ref: Roche | Image: Roche